Therefore, the β-catenin signalling pathway is another potential target for colon cancer treatment.11 Here, we demonstrate that MEK inhibitor sensitivity was driven by the PIK3CA genotype in KRAS mutant colon cancer cells. The gene discussed is MAP2K7; the disease is malignant colon neoplasm.